H.C. Wainwright Reiterates Their Buy Rating on Pieris Pharmaceuticals (PIRS)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Pieris Pharmaceuticals (PIRS) today and set a price target of $9.00. The company’s shares closed last Friday at $2.78.
According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 41.6% and a 61.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catabasis Pharmaceuticals, and Lineage Cell Therapeutics.
Pieris Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $9.00, representing a 214.7% upside. In a report issued on March 30, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.64 and a one-year low of $1.95. Currently, Pieris Pharmaceuticals has an average volume of 503K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.